We are software builders helping developers in building a better internet. Our CEO, COO, and CTO are all software engineers.

BetterBrain is at the forefront of dementia prevention. We offer the most comprehensive platform to help our members prevent neurodegenerative diseases and optimize their cognition.

We’re building debugging intelligence for modern software teams. BetterBugs captures rich technical context at the moment a bug occurs and turns it into actionable insights for developers.

Bevyl is a pre-seed startup building AI-powered content creation tools for consumer brands, enabling them to produce high-quality social media content at scale without agencies or massive creative teams.

We're an early-stage (pre-seed) VC-backed startup automating RFP proposals for the AEC (Architecture, Engineering, Construction) industry. We are building an agentic AI platform that embeds directly into Microsoft Word, helping firms find and win more work, while serving as their knowledge management hub for all business development.

Big Cartel is dedicated to empowering the independent seller with affordable e-commerce tools. We are a 100% independent, bootstrapped, tight-knit team dedicated to our mission of aiding individuals and small brands in setting up shop and making a living doing what they love.

At Big Health our digital therapeutics — Sleepio for insomnia, Daylight for anxiety, and Spark Direct for depression — provide treatment anytime, anywhere. In pursuit of our mission, we’ve pioneered the first at-scale digital therapeutic business model, in partnership with some of the most prominent global healthcare organizations, including CVS Health and the UK’s NHS.

An early-stage startup with an AI voice agent prototype for restaurants.

BillionToOne is ranked at the top 5% of Y Combinator companies with close to $400M in funding. In June 2024, we closed a $130M Series D resulting in a company valuation of over $1 billion. We have developed a DNA molecular counter that increases cfDNA diagnostic resolution by over 1,000x. Our first product, Unity, is the first and only non-invasive prenatal test that can directly screen an unborn baby and assess its risk for common and severe recessive gene disorders, chromosomal abnormalities, fetal sex, and fetal antigens from a single tube of blood from the pregnant mother.

We are a UK-based not-for-profit Focused Research Organisation (FRO) committed to improving patient outcomes by turning disordered proteins into viable drug targets.